Summary & Overview
Other Musculoskeletal System and Connective Tissue Diagnoses with CC: Inpatient Reimbursement Overview
DRG 565 encompasses inpatient stays for other musculoskeletal and connective tissue diagnoses when a Complication or Comorbidity is present, reflecting increased clinical complexity. This grouping matters for inpatient reimbursement because the Complication or Comorbidity elevates resource use and affects payment under Centers for Medicare & Medicaid Services rules.
DRG 565 Overview
DRG 565 covers admissions for Other Musculoskeletal System and Connective Tissue Diagnoses with Complication or Comorbidity, typically involving non-major orthopedic or connective tissue conditions that require inpatient care and incur additional clinical complexity. This Diagnosis-Related Group is relevant to hospital reimbursement because the presence of a Complication or Comorbidity increases the relative resource use and payment compared with cases without such comorbidity. Common clinical scenarios include exacerbations, infections, or complications related to musculoskeletal or connective tissue disorders that prolong stay or require additional therapies. Understanding this grouping supports accurate inpatient coding and billing under Centers for Medicare & Medicaid Services payment rules.
Clinical Trials
- Acute perioperative management trials: Studies evaluating strategies to optimize short-term outcomes for hospitalized patients with diverse musculoskeletal or connective tissue conditions (eg, complex fractures, severe inflammatory flares, postoperative complications) who have a qualifying complication or comorbidity (CC). These trials test interventions such as multimodal pain protocols, infection prevention bundles, or rapid medical optimization pathways aimed at reducing in-hospital complications, length of stay, and urgent readmissions. Results are directly relevant to inpatient teams and payers because reducing complications and LOS can lower costs and improve DRG-based reimbursement performance.
- Comparative effectiveness and care pathway studies: Pragmatic trials comparing different inpatient or peri-discharge care approaches for heterogeneous musculoskeletal/connective tissue diagnoses with CCs—for example, inpatient rehabilitation timing versus standard therapy, early versus delayed surgical stabilization, or corticosteroid-sparing versus standard immunomodulatory strategies in systemic inflammatory conditions complicated by comorbidity. These studies enroll real-world patients with coexisting medical issues (cardiopulmonary disease, diabetes, obesity) to determine which pathways lead to better functional recovery, fewer complications, or lower total episode-of-care costs. Findings inform clinical decision-making, resource allocation, and bundled payment models by identifying care patterns that improve outcomes within this DRG population.
- Post-discharge outcomes and healthcare utilization cohort studies: Observational and interventional research tracking readmissions, outpatient resource use, long-term functional status, and quality-of-life after hospital discharge for patients assigned to this DRG who have complicating comorbidities. These studies often evaluate transitional care interventions (care coordination, home-based rehab, medication reconciliation) and risk stratification tools to predict high utilizers and prevent downstream events. For providers and payers, evidence from these studies supports targeted post-acute services to reduce costly readmissions and optimize total cost of care across the recovery continuum.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.